200212-60721

CourtBoard of Veterans' Appeals
DecidedAugust 31, 2021
Docket200212-60721
StatusUnpublished

This text of 200212-60721 (200212-60721) is published on Counsel Stack Legal Research, covering Board of Veterans' Appeals primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
200212-60721, (bva 2021).

Opinion

Citation Nr: AXXXXXXXX Decision Date: 08/31/21 Archive Date: 08/31/21

DOCKET NO. 200212-60721 DATE: August 31, 2021

ORDER

Entitlement to a disability rating in excess of 40 percent for prostate cancer is denied.

FINDINGS OF FACT

The preponderance of the evidence shows that therapeutic procedures to treat the Veteran's prostate cancer have ceased, there has been no local recurrence or metastasis of his prostate cancer, and his residuals neither include renal dysfunction or a need to wear absorbent materials which must be changed more than four times per day or the uses an appliance at any time during the pendency of the appeal.

CONCLUSION OF LAW

The criteria for a disability rating in excess of 40 percent for prostate cancer have not been met at all times during the pendency of the appeal. 38 U.S.C. §§ 1155, 5107; 38 C.F.R. §§ 3.102, 4.1, 4.2, 4.3, 4.7, 4.14, 4.115a, 4.115b, Diagnostic Codes 7527, 7528.

REASONS AND BASES FOR FINDING AND CONCLUSION

The Veteran served on active duty from May 1968 to May 1971 in the United States Army.

This appeal comes to the Board of Veterans' Appeal (Board) under the Appeals Modernization Act (AMA) review system. See 84 Fed. Reg. 138 (Jan. 18, 2019).

In this regard, the February 2020 VA form 10182, Decision Review Request: Board Appeal (AMA Notice of Disagreement), the Veteran elected the Direct Review Lane. Therefore, the Board may only consider the evidence of record at the time of the decision on appeal.

Initially, as to the characterization of the issue on appeal, the Board finds that the issue is a claim for an increased rating and not a restoration claim because, as discussed in more detail below, the Veteran's prostate cancer is rated under 38 C.F.R. §§ 4.115b, Diagnostic Code 7528 and it provides only a temporary 100 percent rating for prostate cancer for the first six months following the cessation of surgical, x-ray, antineoplastic chemotherapy, or other therapeutic procedure and thereafter, if there is no local reoccurrence or metastasis, it is rated on residuals as voiding dysfunction or renal dysfunction.

Lastly, the Board notes that evidence was added to the claims file during a period of time when new evidence was not allowed. As the Board is deciding the claims of entitlement to an increased rating for prostate cancer, it may not consider this evidence in its decision. 38 C.F.R. § 20.300. The Veteran may file a Supplemental Claim and submit or identify this evidence. 38 C.F.R. § 3.2501. If the evidence is new and relevant, VA will issue another decision on the claim, considering the new evidence in addition to the evidence previously considered. Id. Specific instructions for filing a Supplemental Claim are included with this decision.

The Rating Claim

The Veteran claims, in substance that at all times during the pendency of his appeal he is entitled to a higher rating for his prostate cancer.

Disability evaluations are determined by the application of a schedule of ratings which is based, as far as can practically be determined, on the average impairment of earning capacity. 38 U.S.C. § 1155; 38 C.F.R. § 4.1. Each service-connected disability is rated on the basis of specific criteria identified by a Diagnostic Code. 38 C.F.R. § 4.27. When rating the Veteran's service-connected disability, the entire medical history must be borne in mind. Schafrath v. Derwinski, 1 Vet. App. 589 (1991). Separate higher or lower compensable evaluations may be assigned for separate periods of time if such distinct periods are shown by the competent evidence of record during the appeal, a practice known as "staged" ratings. See Hart v. Mansfield, 21 Vet. App. 505 (2007); Fenderson v. West, 12 Vet. App. 119, 126 (1999).

Regulations require that where there is a question as to which of two evaluations is to be applied, the higher evaluation will be assigned if the disability picture more nearly approximates the criteria required for that rating. Otherwise, the lower rating will be assigned. 38 C.F.R. § 4.7.

The assignment of a particular diagnostic code is "completely dependent on the facts of a particular case." See Butts v. Brown, 5 Vet. App. 532, 538 (1993). One diagnostic code may be more appropriate than another based on such factors as an individual's relevant medical history, the current diagnosis and demonstrated symptomatology. Any change in a diagnostic code by VA must be specifically explained. Pernorio v. Derwinski, 2 Vet. App. 625 (1992).

In evaluating the evidence, the Board has been charged with the duty to assess the credibility and weight given to evidence. Davidson v. Shinseki, 581 F. 3d 1313 (Fed. Cir. 2009); Jandreau v. Nicholson, 492 F. 3d 1372 (Fed. Cir. 2007). Indeed, the Court has declared that in adjudicating a claim, the Board has the responsibility to do so. Bryan v. West, 13 Vet. App. 482, 488-89 (2000). In doing so, the Board is free to favor one medical opinion over another, provided it offers an adequate basis for doing so. Owens v. Brown, 7 Vet. App. 429, 433 (1995).

Except as otherwise provided by law, a claimant has the responsibility to present and support a claim for benefits under the laws administered by VA. VA shall consider all information and medical and lay evidence of record. Where there is an approximate balance of positive and negative evidence regarding any issue material to the determination of a matter, VA shall give the benefit of the doubt to the claimant. 38 U.S.C. § 5107; 38 C.F.R. § 3.102; see also Gilbert v. Derwinski, 1 Vet. App. 49, 53 (1990).

The Veteran's prostate cancer is rated as 40 percent disabling under 38 C.F.R. §§ 4.115b, Diagnostic Code 7528.

In this regard, under Diagnostic Code 7527 prostate gland injuries are rated as voiding dysfunction or renal dysfunction, whichever is predominant.

Under Diagnostic Code 7528 malignant neoplasms of the genitourinary system are rated as 100 percent disabling. Note: Following the cessation of surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure, the rating of 100 percent shall continue with a mandatory VA examination at the expiration of six months. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter. If there has been no local recurrence or metastasis, rate on residuals as voiding dysfunction or renal dysfunction, whichever is predominant.

Renal dysfunction is rated under 38 C.F.R. § 4.115a, Diagnostic Code 7101.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Davidson v. SHINSEKI
581 F.3d 1313 (Federal Circuit, 2009)
Jandreau v. Nicholson
492 F.3d 1372 (Federal Circuit, 2007)
Brian J. Hart v. Gordon H. Mansfield
21 Vet. App. 505 (Veterans Claims, 2007)
Gilbert v. Derwinski
1 Vet. App. 49 (Veterans Claims, 1990)
Colvin v. Derwinski
1 Vet. App. 171 (Veterans Claims, 1991)
Schafrath v. Derwinski
1 Vet. App. 589 (Veterans Claims, 1991)
Pernorio v. Derwinski
2 Vet. App. 625 (Veterans Claims, 1992)
Butts v. Brown
5 Vet. App. 532 (Veterans Claims, 1993)
Owens v. Brown
7 Vet. App. 429 (Veterans Claims, 1995)
Fenderson v. West
12 Vet. App. 119 (Veterans Claims, 1999)
Bloom v. West
12 Vet. App. 185 (Veterans Claims, 1999)
Bryan v. West
13 Vet. App. 482 (Veterans Claims, 2000)

Cite This Page — Counsel Stack

Bluebook (online)
200212-60721, Counsel Stack Legal Research, https://law.counselstack.com/opinion/200212-60721-bva-2021.